Literature DB >> 30502301

Medical management of haemorrhagic hereditary telangiectasia in adult patients.

Antoni Riera-Mestre1, Jesús Ribas2, José Castellote3.   

Abstract

Hereditary haemorrhagic telangiectasia (HHT) is an autosomal dominant inherited Rare Disease that causes a systemic anomalous vascular overgrowth. The approach and follow-up of these patients should be from multidisciplinary units. Its diagnosis is carried out according to Curaçao clinical Criteria. Telangiectasia in the nasal mucosa cause recurrent epistaxis, the main symptom of HHT and difficult to control. The three types of hepatic shunting, hepatic artery to hepatic vein, hepatic artery to portal vein or to portal vein to hepatic vein, can cause high-output heart failure, portal hypertension or porto-systemic encephalopathy, respectively. These types of vascular involvement can be established using computerised tomography. Pulmonary arteriovenous fistula should be screened for all HHT patients by contrast echocardiography. The main objective is to review the management of epistaxis, liver and lung involvement of the adult patient with HHT.
Copyright © 2018 Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Enfermedades Minoritarias; Haemorrhagic hereditary telangiectasia; Rare diseases; Telangiectasia hemorrágica hereditaria; Vascular malformation; malformación vascular

Mesh:

Year:  2018        PMID: 30502301     DOI: 10.1016/j.medcli.2018.09.015

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  7 in total

1.  Pulmonary arteriovenous malformation and inherent complications with solitary lung nodule biopsy-literature overview and case report.

Authors:  Cung-Van Cong; Dinh-Van Luong; Tran-Thi Tuan Anh; Nguyen-Le Nhat Minh; Tran-Thi Ly; Nguyen Minh Duc
Journal:  Radiol Case Rep       Date:  2022-05-06

2.  Natural history of patients with venous thromboembolism and hereditary hemorrhagic telangiectasia. Findings from the RIETE registry.

Authors:  Antoni Riera-Mestre; José María Mora-Luján; Javier Trujillo-Santos; Jorge Del Toro; José Antonio Nieto; José María Pedrajas; Raquel López-Reyes; Silvia Soler; Aitor Ballaz; Pau Cerdà; Manel Monreal
Journal:  Orphanet J Rare Dis       Date:  2019-08-09       Impact factor: 4.123

3.  PI3K (Phosphatidylinositol 3-Kinase) Activation and Endothelial Cell Proliferation in Patients with Hemorrhagic Hereditary Telangiectasia Type 1.

Authors:  Adriana Iriarte; Agnes Figueras; Pau Cerdà; José María Mora; Anna Jucglà; Rosa Penín; Francesc Viñals; Antoni Riera-Mestre
Journal:  Cells       Date:  2019-08-24       Impact factor: 6.600

4.  Current HHT genetic overview in Spain and its phenotypic correlation: data from RiHHTa registry.

Authors:  Rosario Sánchez-Martínez; Adriana Iriarte; José María Mora-Luján; José Luis Patier; Daniel López-Wolf; Ana Ojeda; Miguel Angel Torralba; María Coloma Juyol; Ricardo Gil; Sol Añón; Joel Salazar-Mendiguchía; Antoni Riera-Mestre
Journal:  Orphanet J Rare Dis       Date:  2020-06-05       Impact factor: 4.123

5.  Gender differences in hereditary hemorrhagic telangiectasia severity.

Authors:  J M Mora-Luján; A Iriarte; E Alba; M A Sánchez-Corral; P Cerdà; F Cruellas; Q Ordi; X Corbella; J Ribas; J Castellote; A Riera-Mestre
Journal:  Orphanet J Rare Dis       Date:  2020-03-02       Impact factor: 4.123

Review 6.  Rethinking growth factors: the case of BMP9 during vessel maturation.

Authors:  Ferran Medina-Jover; Antoni Riera-Mestre; Francesc Viñals
Journal:  Vasc Biol       Date:  2022-02-07

7.  Gastrointestinal Bleeding in Patients with Hereditary Hemorrhagic Telangiectasia: Risk Factors and Endoscopic Findings.

Authors:  José María Mora-Luján; Adriana Iriarte; Esther Alba; Miguel Ángel Sánchez-Corral; Ana Berrozpe; Pau Cerdà; Francesc Cruellas; Jesús Ribas; Jose Castellote; Antoni Riera-Mestre
Journal:  J Clin Med       Date:  2019-12-28       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.